Noah Rosenberg takes chief medical officer role at Esperion
Will develop and manage the firm’s clinical programmes
Over the past decade, Dr Rosenberg has held senior posts in the pharmaceutical industry, including leadership roles in medical affairs, clinical development and administration in the US and globally at Pfizer, Sanofi and Forest Labs. He has experience working on compounds in all phases of drug development including late stage drugs such as Lipitor and Lantus. Most recently at Forest Research Institute, he led the in-licensing of the GK1-399 programme.
‘Esperion has an established reputation for productivity and success and I look forward to moving novel therapies such as ETC-1002 further along in clinical development,’ Dr Rosenberg said.
You may also like
Regulatory
The foundations of pharmaceutical compliance for beginners
Whether you’re stepping into the pharmaceutical industry for the first time or pivoting into a compliance or quality assurance role after years of experience, mastering the fundamentals of quality and regulatory compliance is vital to your success—and to the success of your organisation
Research & Development
Corteria Pharmaceuticals initiates Phase II trial in heart failure and Phase I trial in obesity
Corteria, a clinical-stage biopharmaceutical company focused on the development of transformative therapies for heart failure and obesity, announces the clinical advancement of its two first-in-class corticotropin‑releasing factor receptor 2 (CRF2) agonists: COR‑1167 and COR‑1389